Tricia Reich
Family · Lumberton, NCNPI 1841617321
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 206 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 22.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $1,329 and has fallen 94.1% since, to $78 in 2024.
Across 206 payments — averaging $15.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$742
- Merck$316
- Boehringer Ingelheim$225
- Lilly USA, LLC$195
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$167
- AstraZeneca$161
- plus $1K from 23 others
What the payments were for
- Food & beverage$3,236100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 53 | $742 |
| Merck | 18 | $316 |
| Boehringer Ingelheim | 15 | $225 |
| Lilly USA, LLC | 16 | $195 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 9 | $167 |
| AstraZeneca | 11 | $161 |
| GSK | 9 | $146 |
| Bayer | 7 | $130 |
| Johnson & Johnson | 7 | $109 |
| Amgen | 8 | $108 |
| Sanofi-aventis U.S. LLC | 6 | $106 |
| Ironwood Pharmaceuticals, Inc | 6 | $106 |
| Novartis | 6 | $104 |
| Abbott | 4 | $96 |
| Exact Sciences | 3 | $70 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $69 |
| Pfizer | 4 | $59 |
| AbbVie | 3 | $47 |
| Sunovion Pharmaceuticals Inc. | 3 | $46 |
| Amarin Pharma, Inc. | 3 | $42 |
| Nestle Healthcare Nutrition Inc. | 2 | $42 |
| Hikma Pharmaceuticals USA | 2 | $25 |
| E.r. Squibb & Sons, L.L.C. | 2 | $25 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $20 |
| Jazz Pharmaceuticals Inc. | 1 | $19 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $19 |
| Edwards Lifesciences | 1 | $16 |
| Idorsia Pharmaceuticals US Inc | 1 | $13 |
| Eyevance Pharmaceuticals LLC | 1 | $12 |
How this compares
$3,236 in reported general payments places this provider in the 85th percentile of 4,522 family providers in North Carolina.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Rosuvastatin Calcium | 12 | $305 |
| Atorvastatin Calcium | 22 | $284 |
| Potassium Chloride | 12 | $162 |
| Amlodipine Besylate | 14 | $88 |
Paid to pharmacies, not to this prescriber.
Other family in Lumberton
- Leslie ByrneFayetteville$482K
- Michele CerraRaleigh$332K
- Anne LakeArchdale$306K
- Carrie PettitRaleigh$298K
- Nicole RothmanDurham$268K
- Meredith LeaYanceyville$253K
- Jennifer GibbsRaleigh$216K
- Juanita PerkinsDurham$213K
- Teresa DossWilmington$137K
- Debra ScottCharlotte$129K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.